Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution

Blood (2010) 116 (16): 3080–3088.

https://doi.org/10.1182/blood-2010-05-286856

Published: 2010

Journal Articles

Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients

Bart Keymeulen, Sophie Candon, Samira Fafi-Kremer, Anette Ziegler, Marianne Leruez-Ville, Chantal Mathieu, Evy Vandemeulebroucke, Markus Walter, Laurent Crenier, Eric Thervet, Christophe Legendre, Denis Pierard, Geoff Hale, Herman Waldmann, Jean-François Bach, Jean Marie Seigneurin, Daniel Pipeleers, Lucienne Chatenoud

Blood (2010) 115 (6): 1145–1155.

https://doi.org/10.1182/blood-2009-02-204875

Published: 2010

Includes: Supplemental data

Journal Articles

A Retrospective Study of Alemtuzumab Level, T Cell Chimerism and Graft Versus Host Disease Using Intermediate Dose Alemtuzumab for Matched Related and Matched Unrelated Reduced Intensity Transplantation.

Andrew Charlton, MD, Laura Spence, MD, Venetia Bigley, MD, Natasha Groves, PhD, Geoff Hale, PhD, Sarah Pagan, BSc, Brie E Turner, PhD, Gail Jones, MD, PhD, Graham H Jackson, MD, PhD, Anne M Dickinson, PhD, Matthew Collin, MD, PhD

Blood (2009) 114 (22): 3333.

https://doi.org/10.1182/blood.V114.22.3333.3333

Published: 2009

Journal Articles

Enhanced Potency of Glycoengineered Anti-CD52 Monoclonal Antibodies (MAbs).

Martin J.S. Dyer, MD, PhD, Samuel Moser, PhD, Peter Brünker, PhD, Pru Bird, PhD, Neil Almond, PhD, Ursula Püentener, PhD, Luise M.W. Wheat, PhD, Emma Bolam, Eleanor Berrie, PhD, Roger Grau, PhD, Emma Buckby, Ben Kennedy, MD, Richard Stebbings, PhD, Geoff Hale, PhD, Pablo Umana, PhD

Blood (2005) 106 (11): 2958.

https://doi.org/10.1182/blood.V106.11.2958.2958

Published: 2005

Journal Articles

Myeloablative Conditioning Is Well Tolerated by Older Patients Receiving T-Cell Depleted Grafts.

Nicolas Novitzky, MD, PhD, Valda Thomas, Geoff Hale, Herman Waldmann

Blood (2005) 106 (11): 5266.

https://doi.org/10.1182/blood.V106.11.5266.5266

Published: 2005

Journal Articles

Improved Long Term Survival with Minimal GVHD after Myeloablative Unrelated Donor Stem Cell Transplantation Using In Vitro and In Vivo T Cell Depletion with CAMPATH-1H.

Peter A. von dem Borne, Floor Beaumont, Ingrid Starrenburg, Machteld A. Oudshoorn, Geoff Hale, J.H. Frederik Falkenburg, Willem E. Fibbe, Roel Willemze, Renee M.Y. Barge

Blood (2004) 104 (11): 2761.

https://doi.org/10.1182/blood.V104.11.2761.2761

Published: 2004

Journal Articles

Favourable Impact on Acute and Chronic Graft-Versus-Host Disease with Cyclophosphamide and In-Vivo Anti-CD52 Monoclonal Antibodies for Marrow Transplantation from HLA-Identical Sibling Donors for Acquired Aplastic Anaemia.

Vikas Gupta, Sarah E. Ball, Qi-long Yi, Deborah Sage, Shaun R. McCann, Mark Lawler, Miguel Ortin, Mylene Freires, Geoff Hale, Hermann Waldmann, Edward C. Gordon-Smith, Judith C.W. Marsh

Blood (2004) 104 (11): 3333.

https://doi.org/10.1182/blood.V104.11.3333.3333

Published: 2004

Journal Articles

Radiotherapy-Based Conditioning Is Effective Immunosuppression for Patients Undergoing Transplantation with T-Cell Depleted Stem Cell Grafts for Severe Aplasia.

Nicolas Novitzky, MD, PhD, Valda Thomas, Helen Stubbings, Geoff Hale, Herman Waldmann

Blood (2004) 104 (11): 1819.

https://doi.org/10.1182/blood.V104.11.1819.1819

Published: 2004

Journal Articles

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration

Geoff Hale, Peppy Rebello, Lee R. Brettman, Chris Fegan, Ben Kennedy, Eva Kimby, Mike Leach, Jeanette Lundin, Håkan Mellstedt, Paul Moreton, Andy C. Rawstron, Herman Waldmann, Anders Osterborg, Peter Hillmen

Blood (2004) 104 (4): 948–955.

https://doi.org/10.1182/blood-2004-02-0593

Published: 2004

Journal Articles

Reconstitution of the Epstein-Barr virus–specific cytotoxic T-lymphocyte response following T-cell–depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation

Suparno Chakrabarti, Donald W. Milligan, Deenan Pillay, Stephen Mackinnon, Kathleen Holder, Narinder Kaur, Dorothy McDonald, Christopher D. Fegan, Herman Waldmann, Geoff Hale, Alan Rickinson, Neil Steven

Blood (2003) 102 (3): 839–842.

https://doi.org/10.1182/blood.V102.3.839

Published: 2003

Journal Articles

Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications

Emma C. Morris, Peppy Rebello, Kirsty J. Thomson, Karl S. Peggs, Charalampia Kyriakou, Anthony H. Goldstone, Stephen Mackinnon, Geoff Hale

Blood (2003) 102 (1): 404–406.

https://doi.org/10.1182/blood-2002-09-2687

Published: 2003

Journal Articles

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)

Jeanette Lundin, Eva Kimby, Magnus Björkholm, Per-Anders Broliden, Fredrik Celsing, Viktoria Hjalmar, Lars Möllgård, Peppy Rebello, Geoff Hale, Herman Waldmann, Håkan Mellstedt, Anders Österborg

Blood (2002) 100 (3): 768–773.

https://doi.org/10.1182/blood-2002-01-0159

Published: 2002

Journal Articles

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution

Suparno Chakrabarti, Stephen Mackinnon, Raj Chopra, Panagiotis D. Kottaridis, Karl Peggs, Peter O'Gorman, Ronjon Chakraverty, Timothy Marshall, Husam Osman, Premini Mahendra, Charles Craddock, Herman Waldmann, Geoff Hale, Christopher D. Fegan, Kwee Yong, Anthony H. Goldstone, David C. Linch, Donald W. Milligan

Blood (2002) 99 (12): 4357–4363.

https://doi.org/10.1182/blood.V99.12.4357

Published: 2002

Journal Articles

Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution

Phennapha Klangsinsirikul, G. Ian Carter, Jennifer L. Byrne, Geoff Hale, Nigel H. Russell

Blood (2002) 99 (7): 2586–2591.

https://doi.org/10.1182/blood.V99.7.2586

Published: 2002

Journal Articles

Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen

Blood (2002) 99 (3): 1071–1078.

https://doi.org/10.1182/blood.V99.3.1071

Published: 2002

Journal Articles

Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy

Andy C. Rawstron, Ben Kennedy, Paul A. S. Evans, Faith E. Davies, Stephen J. Richards, Andy P. Haynes, Nigel H. Russell, Geoff Hale, Gareth J. Morgan, Andrew S. Jack, Peter Hillmen

Blood (2001) 98 (1): 29–35.

https://doi.org/10.1182/blood.V98.1.29

Published: 2001

Journal Articles

In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation

Blood (2000) 96 (7): 2419–2425.

https://doi.org/10.1182/blood.V96.7.2419

Published: 2000

Journal Articles

Children With Acute Lymphoblastic Leukemia Who Receive T-Cell–Depleted HLA Mismatched Marrow Allografts From Unrelated Donors Have an Increased Incidence of Primary Graft Failure but a Similar Overall Transplant Outcome

Ann Green, Emer Clarke, Linda Hunt, Andrew Canterbury, Alan Lankester, Geoff Hale, Herman Waldmann, Sally Goodman, Jacqueline M. Cornish, David I. Marks, Colin G. Steward, Anthony Oakhill, Derwood H. Pamphilon

Blood (1999) 94 (7): 2236–2246.

https://doi.org/10.1182/blood.V94.7.2236.419k04_2236_2246

Published: 1999

Journal Articles

Improving the Outcome of Bone Marrow Transplantation by Using CD52 Monoclonal Antibodies to Prevent Graft-Versus-Host Disease and Graft Rejection

Geoff Hale, Mei-Jie Zhang, Donald Bunjes, H. Grant Prentice, David Spence, Mary M. Horowitz, A. John Barrett, Herman Waldmann

Blood (1998) 92 (12): 4581–4590.

https://doi.org/10.1182/blood.V92.12.4581

Published: 1998

Journal Articles

Reconstitution of the T-Cell Compartment After Bone Marrow Transplantation: Restoration of the Repertoire by Thymic Emigrants

Florence Dumont-Girard, Etienne Roux, René A. van Lier, Geoff Hale, Claudine Helg, Bernard Chapuis, Michel Starobinski, Eddy Roosnek

Blood (1998) 92 (11): 4464–4471.

https://doi.org/10.1182/blood.V92.11.4464

Published: 1998

NARROW

Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution

Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients

A Retrospective Study of Alemtuzumab Level, T Cell Chimerism and Graft Versus Host Disease Using Intermediate Dose Alemtuzumab for Matched Related and Matched Unrelated Reduced Intensity Transplantation.

Enhanced Potency of Glycoengineered Anti-CD52 Monoclonal Antibodies (MAbs).

Myeloablative Conditioning Is Well Tolerated by Older Patients Receiving T-Cell Depleted Grafts.

Improved Long Term Survival with Minimal GVHD after Myeloablative Unrelated Donor Stem Cell Transplantation Using In Vitro and In Vivo T Cell Depletion with CAMPATH-1H.

Favourable Impact on Acute and Chronic Graft-Versus-Host Disease with Cyclophosphamide and In-Vivo Anti-CD52 Monoclonal Antibodies for Marrow Transplantation from HLA-Identical Sibling Donors for Acquired Aplastic Anaemia.

Radiotherapy-Based Conditioning Is Effective Immunosuppression for Patients Undergoing Transplantation with T-Cell Depleted Stem Cell Grafts for Severe Aplasia.

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration

Reconstitution of the Epstein-Barr virus–specific cytotoxic T-lymphocyte response following T-cell–depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation

Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution

Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution

Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen

Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy

In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation

Children With Acute Lymphoblastic Leukemia Who Receive T-Cell–Depleted HLA Mismatched Marrow Allografts From Unrelated Donors Have an Increased Incidence of Primary Graft Failure but a Similar Overall Transplant Outcome

Improving the Outcome of Bone Marrow Transplantation by Using CD52 Monoclonal Antibodies to Prevent Graft-Versus-Host Disease and Graft Rejection

Reconstitution of the T-Cell Compartment After Bone Marrow Transplantation: Restoration of the Repertoire by Thymic Emigrants

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only